Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 18, 2026

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

7.8K

Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.

Simona Rolla1, Stefania Federica De Mercanti1, Valentina Bardina1

  • 1Clinical and Biological Sciences Department, University of Torino, San Luigi Gonzaga Hospital, Orbassano (TO), Italy.

Journal of Neuroimmunology
|November 21, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

The journal of headache and pain·2026
Same author

Quality of life domains revised by people with multiple sclerosis and healthcare professionals for adaptive measure development.

PloS one·2026
Same author

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort.

Drugs - real world outcomes·2026
Same author

Integrating peripheral immune control and brain health in the multiple sclerosis continuum.

Lancet (London, England)·2026
This summary is machine-generated.

Alemtuzumab treatment for relapsing remitting multiple sclerosis (RRMS) may not affect CD4+ T cell percentages in some patients. This atypical response warrants further investigation into CD4+ cell counts as a predictor of treatment efficacy.

Area of Science:

  • Immunology
  • Neurology
  • Clinical Medicine

Background:

  • Alemtuzumab is a monoclonal antibody used to treat relapsing remitting multiple sclerosis (RRMS).
  • It functions by depleting lymphocytes, including CD4+ T cells, which are implicated in MS pathogenesis.
  • Understanding treatment response variability is crucial for optimizing patient outcomes.

Observation:

  • Two patients with persistent RRMS activity despite alemtuzumab treatment exhibited unusual CD4+ T cell dynamics.
  • While overall lymphocyte counts decreased with treatment, their CD4+ T cell percentages remained largely unaffected.
  • Pre-treatment CD4+ T cell percentages were already slightly below the normal range in these patients.

Findings:

  • Atypical CD4+ T cell population behavior was observed in patients with persistent disease activity under alemtuzumab therapy.
Keywords:
AlemtuzumabCD4+ lymphocytesImmune reconstitutionMultiple sclerosisTreatment response

Related Experiment Videos

Last Updated: Feb 18, 2026

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

7.8K
  • The CD4+ T cell percentage showed minimal impact from alemtuzumab, contrasting with expected lymphopenia.
  • These findings suggest a potential dissociation between overall lymphocyte depletion and CD4+ T cell response.

    • Implications:

    • CD4+ T cell percentage evaluation may serve as a biomarker for predicting individual clinical response to alemtuzumab.
    • Further research is needed to elucidate the mechanisms behind this atypical CD4+ T cell behavior.
    • This could lead to personalized treatment strategies for RRMS patients receiving alemtuzumab.